Comparison of Different HIV-1 Resistance Interpretation Tools for Next-Generation Sequencing in Italy
Authors:
- Daniele ArmeniaDADaniele Armenia
- Luca CariotiLCLuca Carioti
- Valeria MicheliVMValeria Micheli
- Isabella BonIBIsabella Bon
- Tiziano AlliceTATiziano Allice
- Celestino BonuraCBCelestino Bonura
- Bianca BruzzoneBBBianca Bruzzone
- Fiorenza BracchittaFBFiorenza Bracchitta
- Francesco CeruttiFCFrancesco Cerutti
- Giovanni Maurizio GiammancoGGGiovanni Maurizio Giammanco
- Federica StefanelliFSFederica Stefanelli
- Maria Addolorata BonifacioMaria Addolorata Bonifacio
Open Access
Abstract
Background: Next-generation sequencing (NGS) is gradually replacing Sanger sequencing for HIV genotypic drug resistance testing (GRT). This work evaluated the concordance among different NGS-GRT interpretation tools in a real-life setting. Methods: Routine NGS-GRT data were generated from viral RNA at 11 Italian laboratories with the AD4SEQ HIV-1 Solution v2 commercial kit. NGS results were interpreted by the SmartVir system provided by the kit and by two online tools (HyDRA Web and Stanford HIVdb). NGS-GRT was considered valid when the coverage was >100 reads (100×) at each PR/RT/IN resistance-associated position listed in the HIVdb 9.5.1 algorithm. Results: Among 629 NGS-GRT, 75.2%, 74.2%, and 70.9% were valid according to SmartVir, HyDRA Web, and HIVdb. Considering at least two interpretation tools, 463 (73.6%) NGS-GRT had a valid coverage for resistance analyses. The proportion of valid samples was affected by viremia 10% showed fair concordance among different interpretation tools. Conclusion: This Italian survey on NGS resistance testing suggests that viremia levels and HIV subtype affect NGS-GRT coverage. Within the current routine method for NGS-GRT, only mutations with frequency >10% seem reliably detected across different interpretation tools.Keywords
This publication has 29 references indexed in Scilit:
- Learning from Persistent Viremia: Mechanisms and Implications for Clinical Care and HIV-1 CureCurrent HIV/AIDS Reports, 2023
- Shall I trust the report? Variable performance of Sanger sequencing revealed by deep sequencing on HIV drug resistance mutation detectionInternational Journal of Infectious Diseases, 2020
- Performance comparison of next generation sequencing analysis pipelines for HIV-1 drug resistance testingScientific Reports, 2020
- Prospective Evaluation of the Vela Diagnostics Next-Generation Sequencing Platform for HIV-1 Genotypic Resistance TestingThe Journal of Molecular Diagnostics, 2019
- A MiSeq-HyDRA platform for enhanced HIV drug resistance genotyping and surveillanceScientific Reports, 2019
- Performance comparison of deep sequencing platforms for detecting HIV‐1 variants in the pol geneJournal of Medical Virology, 2018
- Promises and pitfalls of Illumina sequencing for HIV resistance genotypingVirus Research, 2017
- Deep sequencing for HIV-1 clinical managementVirus Research, 2017
- Evaluation of GS Junior and MiSeq next-generation sequencing technologies as an alternative to Trugene population sequencing in the clinical HIV laboratoryJournal of Virological Methods, 2015
- Performance of HIV-1 Drug Resistance Testing at Low-Level Viremia and Its Ability to Predict Future Virologic Outcomes and Viral Evolution in Treatment-Naive IndividualsClinical Infectious Diseases, 2014